🔥 Don’t Miss Out on our Blind Box Giveaway with a minimum spend of $280! 🔥 Don’t Miss Out on our Blind Box Giveaway with a minimum spend of $280! 🔥 Don’t Miss Out on our Blind Box Giveaway with a minimum spend of $280!

🔥 Don’t Miss Out on our Blind Box Giveaway with a minimum spend of $280! 🔥 Don’t Miss Out on our Blind Box Giveaway with a minimum spend of $280! 🔥 Don’t Miss Out on our Blind Box Giveaway with a minimum spend of $280!

Disitamab vedotin

Categories, Drug Discovery & Development, Immunooncology, Inhibitors and Compound Libraries, Inhibitory Antibodies

“Yeast Live-or-Dye™ Fixable Live/Dead Staining Kit” has been added to your cart. View cart

Disitamab vedotin

Disitamab vedotin

Add to cart

Categories: Categories Drug Discovery & Development Immunooncology Inhibitors and Compound Libraries Inhibitory Antibodies Tags: 2136633-23-1 Disitamab vedotin inhibit Inhibitor RC48 Brand: TargetMol

Description

Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.

[accordions]
[accordion title= “Biological Description“]

Description	Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.
In vitro	The antibody part was a humanized monoclonal antibody targeting HER2, the small molecule toxin was monomethyl auristatin E (MMAE), a synthetic antineoplastic agent. A protease cleavable linker covalently attached MMAE to the antibody[2].

[/accordion]

[accordions]
[accordion title= “References and Literature“]

1. Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935.2. Jiang J, et al. Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37.

[/accordion]

HOW CAN WE HELP YOU? Our specialists are to help you find the best product for your application. We will be happy to help you find the right product for the job.

NEWSLETTER

We gladly support you by keeping you updated on our latest products and the developments around our services.

Our Featured Solutions

Animal Models (Preclinical)
Bioprocess
Cell Culture
Cell Imaging & Analysis
Cells & Tissue Repository
Exosome
Growth Factors, Recombinant Proteins
Laboratory Instruments & Equipements
Microfluidics
Western Blotting and Protein Analysis

SERVICES

Customised Soft Hydrogels
Data Analytics
DNA Synthesis Services
GMP Industrial/Clinical Lab Set Up
Innovation Enabler
NTA Particle Analysis
Preclinical and Translational Research
Skin Testing

RESEARCH FIELD

Food & Alternative Protein
Aging & Neuroscience
Cell & Gene Therapy
Drug Discovery & Development
Skin & Personal Care

LEARNING CENTRE

Blog
Technical Content
Product Information

ATLANTIS BIOSCIENCE PTE LTD

362 Upper Paya Lebar Rd, #07-15,
Singapore 534963

+65-8608 0974

[email protected]

LINE info

© 2015-2023 Atlantis Bioscience Pte Ltd. All rights reserved. Co Reg No: 201539516N